HC Wainwright reissued their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) in a research report released on Wednesday, Benzinga reports. They currently have a $18.00 price objective on the stock. HC Wainwright also issued estimates for Entrada Therapeutics’ Q3 2024 earnings at ($0.47) EPS, Q4 2024 earnings at ($0.67) EPS, FY2024 earnings at $0.88 EPS, Q1 2025 earnings at ($0.86) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.94) EPS and FY2025 earnings at ($3.74) EPS.
Entrada Therapeutics Trading Up 1.7 %
Shares of TRDA opened at $16.53 on Wednesday. Entrada Therapeutics has a twelve month low of $10.75 and a twelve month high of $18.17. The company has a market cap of $614.92 million, a P/E ratio of 26.24 and a beta of -0.25. The company’s fifty day simple moving average is $15.58 and its 200-day simple moving average is $14.43.
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. The business had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. Entrada Therapeutics had a return on equity of 41.31% and a net margin of 43.63%. Analysts predict that Entrada Therapeutics will post -0.13 earnings per share for the current fiscal year.
Insider Buying and Selling
Institutional Investors Weigh In On Entrada Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of TRDA. New York State Teachers Retirement System purchased a new position in Entrada Therapeutics during the 1st quarter valued at about $27,000. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics during the first quarter valued at approximately $79,000. Allspring Global Investments Holdings LLC lifted its stake in Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after acquiring an additional 11,965 shares during the period. Strs Ohio lifted its position in Entrada Therapeutics by 792.6% during the fourth quarter. Strs Ohio now owns 24,100 shares of the company’s stock valued at $363,000 after buying an additional 21,400 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Entrada Therapeutics by 25.3% during the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after purchasing an additional 7,452 shares during the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.
Entrada Therapeutics Company Profile
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Read More
- Five stocks we like better than Entrada Therapeutics
- How to Effectively Use the MarketBeat Ratings Screener
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is the Australian Securities Exchange (ASX)
- MarketBeat Week in Review – 8/12 – 8/16
- What is the S&P 500 and How It is Distinct from Other Indexes
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.